Physician profile
Kim M Phan
NPI 1295001592
$9,000.51
in general payments reported to CMS, 2019-2025
60 companies · $1,690 in 2025
The $1,690 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $2,672 · 2021: $785 · 2022: $640 · 2023: $1,032 · 2024: $1,504 · 2025: $1,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,226.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $665.36 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $622.65 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Incyte Corporation | $514.69 | 2020-2025 | Jakafi |
| Pfizer INC. | $458.34 | 2019-2025 | |
| Eisai INC. | $417.52 | 2020-2025 | |
| Amgen INC. | $411.60 | 2020-2023 | Xgeva, Nplate |
| Lilly USA, LLC | $342.64 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $326.44 | 2019-2025 | Pomalyst, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $310.80 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $308.32 | 2020-2025 | Opdivo, Reblozyl |
| Janssen Biotech, INC. | $279.13 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| Karyopharm Therapeutics INC. | $275.43 | 2020-2025 | Xpovio |
| Genzyme Corporation | $236.89 | 2020-2023 | |
| Glaxosmithkline, LLC. | $234.89 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Alexion Pharmaceuticals, INC. | $232.94 | 2019-2023 | Ultomiris |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $218.42 | 2019-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $189.47 | 2019-2025 | Fruzaqla |
| Rigel Pharmaceuticals, INC. | $168.52 | 2020-2024 | Tavalisse, Rezlidhia |
| Puma Biotechnology, INC. | $151.79 | 2019-2025 | |
| Tersera Therapeutics LLC | $151.27 | 2024-2025 | Quzyttir |
| Telix Pharmaceuticals | $147.45 | 2022 | |
| Seagen INC. | $135.29 | 2020-2023 | Adcetris |
| Agios Pharmaceuticals, INC. | $130.77 | 2019-2025 | Pyrukynd |
| Array Biopharma INC | $129.80 | 2022-2025 | Mektovi, Braftovi, Xalkori |
| Neurelis, INC. | $119.72 | 2023 | Valtoco |
| Sobi, INC | $116.69 | 2023-2024 | |
| Pharmaessentia USA Corporation | $114.97 | 2022-2025 | Besremi |
| Beone Medicines USA, INC. | $111.66 | 2025 | Brukinsa, Tevimbra |
| Exelixis INC. | $96.72 | 2019-2020 | |
| Menarini Silicon Biosystems, INC. | $96.08 | 2023 | Cellsearch |
| Astellas Pharma US INC | $86.32 | 2020-2025 | Xtandi |
| Beigene USA, INC. | $84.33 | 2024-2025 | Tevimbra, Brukinsa |
| Blueprint Medicines Corporation | $82.12 | 2020-2024 | Ayvakit |
| Emd Serono, INC. | $72.49 | 2024-2025 | |
| Clovis Oncology, INC. | $69.67 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.32 | 2019-2020 | |
| Genentech USA, INC. | $66.83 | 2020-2024 | Alecensa, Tecentriq, Perjeta |
| Springworks Therapeutics, INC. | $64.86 | 2025 | Ogsiveo |
| Kyowa Kirin, INC. | $61.04 | 2023 | Poteligeo |
| Daiichi Sankyo INC. | $56.56 | 2025 | Enhertu |
| Secura Bio, INC. | $54.53 | 2020 | |
| Ge Healthcare | $48.39 | 2025 | |
| Jazz Pharmaceuticals INC. | $47.67 | 2019-2020 | |
| Taiho Oncology, INC. | $45.36 | 2020-2023 | |
| Tolmar Pharmaceuticals, INC. | $35.50 | 2020 | |
| Intuitive Surgical, INC. | $34.56 | 2024 | |
| Global Blood Therapeutics, INC. | $29.03 | 2020 | |
| Abbvie INC. | $28.25 | 2024 | |
| Revance Therapeutics, INC. | $27.18 | 2024 | Daxxify |
| Novocure INC. | $27.01 | 2025 | Optune Lua (Novottf-200t) |
| Dova Pharmaceuticals | $24.96 | 2020 | |
| Gilead Sciences, INC. | $24.95 | 2024 | Trodelvy |
| Morphosys, US INC. | $24.28 | 2021 | |
| Aveo Pharmaceuticals, INC. | $23.94 | 2024 | |
| Aurobindo Pharma USA, INC. | $18.96 | 2020 | |
| Azurity Pharmaceuticals, INC. | $17.89 | 2024 | Vivimusta |
| Sirtex Medical INC | $16.32 | 2020 | |
| Advanced Accelerator Applications | $15.96 | 2020 | |
| Kite Pharma, INC. | $14.84 | 2024 | Yescarta |
| Eusa Pharma (US) LLC | $13.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.